Recall Informer
medication pill capsule recall cancer

Confirmed Carcinogen Contamination Triggers Another Medication Recall

An ulcer and reflux medication is the newest to join the ever-growing recall list of medicines tainted with a possible carcinogen.

Sandoz Inc., a leading generic pharmaceuticals company, is voluntarily recalling 14 lots of Ranitidine Hydrochloride capsules for containing a possible carcinogen, a substance that could cause cancer.

Recall Affects Generic Zantac Medication

Ranitidine Hydrochloride is the generic name of the well-known antacid and antihistamine medication Zantac, and is used to treat heartburn, stomach ulcers, gastroesophageal reflux disease, and conditions in which the stomach produces too much acid.

The company is recalling the products after they discovered the presence of N-nitrosodimethylamine, or NDMA, in batches of the capsules.

NDMA is a substance that could cause cancer, and is classified as a probable human carcinogen. NDMA is also a known environmental contaminant and can be found in water, vegetables, dairy products, or meats. However, the levels of NDMA in the Ranitidine capsules are above those levels established by the Food and Drug Administration.

Capsules Were Distributed Nationwide

The Sandoz Ranitidine capsules being recalled were distributed to different wholesalers nationwide. The drugmaker says that they will be notifying distributors and customers overnight and are also notifying the public via their website. They are urging wholesalers to immediately stop distribution and are also urging pharmacies to stop dispensing the capsules. Sandoz will arrange for return of all products affected by the recall.

All of the capsules that are affected by the recall can be identified by the NDC number and lot number. The recall includes 30-count, 60-count, and 500-count bottles.

Consumers who might be taking any medication affected by the recall should not stop taking their medication. Instead, patients should contact their physicians or pharmacists for advice on an alternative treatment.

Ranitidine 150mg Capsules 500 count

  • NDC Numer: 0781-2855-05
  • Lot: HD1862
  • Expires: 4/30/2020
  • Manufactured: 4/19/2017

Ranitidine 150mg Capsules 500 count

  • NDC Numer: 0781-2855-05
  • Lot: HP9438
  • Expires: 9/30/2020
  • Manufactured: 9/5/2017

Ranitidine 150mg Capsules 500 count

  • NDC Numer: 0781-2855-05
  • Lot: HP9439
  • Expires: 9/30/2020
  • Manufactured: 9/6/2017

Ranitidine 150mg Capsules 500 count

  • NDC Numer: 0781-2855-05
  • Lot: HP9440
  • Expires: 9/30/2020
  • Manufactured: 9/5/2017

Ranitidine 150mg Capsules 60 count

  • NDC Numer: 0781-2855-60
  • Lot: HC9266
  • Expires: 4/30/2020
  • Manufactured: 4/19/2017

Ranitidine 150mg Capsules 60 count

  • NDC Numer: 0781-2855-60
  • Lot: HD1865
  • Expires: 4/30/2020
  • Manufactured: 4/19/2017

Ranitidine 150mg Capsules 60 count

  • NDC Numer: 0781-2855-60
  • Lot: HP9441
  • Expires: 9/30/2020
  • Manufactured: 9/6/2017

Ranitidine 150mg Capsules 60 count

  • NDC Numer: 0781-2855-60
  • Lot: JK7994
  • Expires: 8/31/2021
  • Manufactured: 8/7/2018

Ranitidine 150mg Capsules 60 count

  • NDC Numer: 0781-2855-60
  • Lot: JK8659
  • Expires: 8/31/2021
  • Manufactured: 8/7/2018

Ranitidine 300mg Capsules 30 count

  • NDC Numer: 0781-2865-31
  • Lot: HD8625
  • Expires: 4/30/2020
  • Manufactured: 4/27/2017

Ranitidine 300mg Capsules 30 count

  • NDC Numer: 0781-2865-31
  • Lot: HD9275
  • Expires: 4/30/2020
  • Manufactured: 4/27/2017

Ranitidine 300mg Capsules 30 count

  • NDC Numer: 0781-2865-31
  • Lot: HU2207
  • Expires: 8/31/2020
  • Manufactured: 8/24/2017

Ranitidine 300mg Capsules 30 count

  • NDC Numer: 0781-2865-31
  • Lot: HX6676
  • Expires: 3/31/2021
  • Manufactured: 3/20/2018

Ranitidine 300mg Capsules 30 count

  • NDC Numer: 0781-2865-31
  • Lot: HX6677
  • Expires: 3/31/2021
  • Manufactured: 3/20/2018